Novartis could gain European Union approval for its novel cholesterol treatment inclisiran by the end of the year, following a nod from a key regulatory committee.
Novartis’ Cholesterol Drug Inclisiran Closes In On EU Approval
Drug Will Be Known As Leqvio
Timing means full EU approval could coincide with US FDA authorization later this year.
More from Business
More from Scrip
• By
Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.
• By
While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology
• By
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies